Quality of Life Measurement
in Neurodegenerative and Related Conditions
Quality of Life Measurement in Neurodegenerative and Related Conditions

Edited by
Crispin Jenkinson
University of Oxford

Michele Peters
University of Oxford

Mark B. Bromberg
University of Utah

Cambridge University Press
978-0-521-82901-4 - Quality of Life Measurement in Neurodegenerative and Related Conditions
Edited by Crispin Jenkinson, Michele Peters and Mark B. Bromberg
Frontmatter
More information
Contents

List of contributors vii
Preface xi

1 Aspects of methodology relevant to patient-reported outcome measures (PROMs) 1
Crispin Jenkinson, Jill Dawson, and Christopher Morris

2 The development and validation of the Parkinson’s Disease Questionnaire and related measures 10
Crispin Jenkinson and Ray Fitzpatrick

3 The Multiple Sclerosis Impact Scale (MSIS-29): Initial development, subsequent revision, lessons learned 24
Jeremy Hobart

4 Patient-reported outcome measurement in motor neuron disease/amyotrophic lateral sclerosis – the ALSAQ-40 and ALSAQ-5 41
Crispin Jenkinson

5 Measuring quality of life in progressive supranuclear palsy: The PSP-QoL 52
Anette Schrag, Caroline Selai, Niall Quinn, Jeremy Hobart, Andrew J. Lees, Irene Litvan, Anthony Lang, James Bower, and David Burn
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Measuring quality of life in multiple system atrophy</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Anette Schrag, Caroline Selai, Christopher Mathias, Philip Low, Jeremy Hobart, and Niall Quinn</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Health-related quality of life in Huntington’s disease</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>Noelle E. Carlozzi and Rebecca E. Ready</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Measuring quality of life in dementia</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Rebecca E. Ready</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Condition-specific instruments to measure the quality of life (QoL) of children and adolescents with cerebral palsy (CP)</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Waters, Amy Shelly, and Elise Davis</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Outcome measures for informal carers of individuals with neurodegenerative conditions</td>
<td>114</td>
</tr>
<tr>
<td></td>
<td>Michele Peters</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Translating patient-reported outcome measures (PROMs) for cross-cultural studies</td>
<td>139</td>
</tr>
<tr>
<td></td>
<td>Michele Peters</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Rasch analysis</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>Jeremy Hobart and Stefan Cano</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>A method for imputing missing questionnaire data</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td>Crispin Jenkinson, Robert Harris, and Ray Fitzpatrick</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Individualized quality of life measurement in neurodegenerative disorders</td>
<td>174</td>
</tr>
<tr>
<td></td>
<td>Mark B. Bromberg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Index</td>
<td>188</td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press [www.cambridge.org](http://www.cambridge.org)
List of contributors

James Bower, MD
Associate Professor of Neurology,
Mayo Clinic College of Medicine,
Rochester, Minnesota, USA

Mark B. Bromberg, MD, PhD
Professor of Neurology,
Department of Neurology,
University of Utah,
Salt Lake City, Utah, USA

David Burn, MD
Professor of Movement Disorder Neurology and
Honorary Consultant Neurologist,
Department of Neurology,
The Royal Victoria Infirmary,
Newcastle upon Tyne, UK

Stefan Cano, PhD, CPsychol
Associate Professor (Senior Lecturer) in Psychometrics,
Peninsula College of Medicine and Dentistry,
University of Plymouth,
Tamar Science Park, Plymouth, UK

Noelle E. Carlozzi, PhD
Assistant Professor,
Center for Rehabilitation Outcomes and
Assessment Research,
Department of Physical Medicine and Rehabilitation,
University of Michigan,
Ann Arbor, Michigan, USA
List of contributors

Elise Davis, PhD
Research Fellow,
McCaughey Centre, VicHealth Centre for the Promotion of Mental Health and Community Wellbeing,
School of Population Health,
University of Melbourne,
Melbourne, Australia

Jill Dawson, DPhil
Senior Research Scientist,
Health Services Research Unit,
Department of Public Health,
University of Oxford,
Oxford, UK

Ray Fitzpatrick, PhD, FMedSci
Professor of Public Health and Primary Care and Head of the Department of Public Health,
University of Oxford, Old Road Campus,
Oxford, UK

Robert Harris, MSc
Research Officer,
Health Services Research Unit,
Department of Public Health,
University of Oxford,
Oxford, UK

Jeremy Hobart, FRCP, PhD
Associate Professor (Reader) in Clinical Neurosciences, Peninsula College of Medicine and Dentistry,
University of Plymouth,
Tamar Science Park, Plymouth, UK

Crispin Jenkinson, DPhil
Professor of Health Services Research and Director,
Health Services Research Unit,
Department of Public Health,
University of Oxford,
Oxford, UK

Anthony Lang, FRCP, MD
Professor of Neurology and Director,
Morton and Gloria Shulman Movement Disorder Centre,
Toronto Western Hospital,
Ontario, Canada

Andrew J. Lees, MD, FRCP, FMedSci
Professor of Neurology, Honorary Consultant Neurologist, and Director,
Reta Lila Weston Institute of Neurological Studies,
University College London,
London, UK

Irene Litvan, MD
Raymond Lee Lebby Professor of Parkinson Disease Research, and Director,
Division of Movement Disorders,
University of Louisville,
Kentucky, USA

Philip Low, MD
Professor of Neurology,
Mayo Clinic College of Medicine,
Rochester, Minnesota, USA

Christopher Mathias, DPhil, DSc, FRCP
Professor of Neurovascular Medicine, and Consultant Physician,
Imperial College, London, and Institute of Neurology,
University College London,
London, UK

Christopher Morris, DPhil
Senior Research Fellow,
Cerebra Research Unit and PenCLARHC,
Peninsula College of Medicine and Dentistry,
University of Exeter,
Exeter, Devon, UK
Michele Peters, PhD
Senior Research Scientist,
Health Services Research Unit,
Department of Public Health,
University of Oxford,
Oxford, UK

Niall Quinn, MD, FRCP
Emeritus Professor of Clinical Neurology,
and Honorary Consultant Neurologist,
Institute of Neurology,
University College London,
London, UK

Rebecca E. Ready, PhD
Associate Professor,
Department of Psychology,
University of Massachusetts,
Amherst, Massachusetts, USA

Anette Schrag, MD
Reader in Neurology,
and Honorary Consultant Neurologist,
Department of Clinical Neurosciences,
Royal Free and University College Medical School,
University College London,
London, UK

Caroline Selai, PhD, CPsychol
Senior Lecturer in Clinical Neuroscience,
Sobell Department for Motor Neuroscience
and Movement Disorders,
and Head of the Education Unit,
Institute of Neurology,
University College London,
London, UK

Amy Shelly, BSc
Project Officer,
Paediatric Integrated Cancer Service,
Children's Cancer Centre,
Royal Children's Hospital,
Parkville, Victoria, Australia

Elizabeth Waters, DPhil
Jack Brockhoff Chair of Child Public Health,
McCaughhey Centre,
VicHealth Centre for the Promotion of Mental
Health and Community Wellbeing,
School of Population Health,
University of Melbourne,
Melbourne, Australia
Preface

Patient-reported outcome measures (PROMs) are now generally regarded as central to the evaluation of health and medical care. This represents a substantial change in opinion from that of just a few decades ago, when the systematic collection of patient reports of their health and quality of life was a relatively new area of research. Today, PROMs feature in routine data collection systems and are seen as important in the monitoring of health care provision. They are increasingly used as primary outcomes measures in trials. Thus, the measurement of quality of life, or what is sometimes referred to as health-related quality of life, has moved into the mainstream of evaluation. In part, this reflects the growth in “patient-centered care,” and the importance now placed on public and patient views of health care. Thus, health care must reflect the needs of patients, and assessment of services must reflect both “consumer” views and “patient-reported outcomes.” This text is evidence of this move toward patient-centered evaluation and documents the development and validation of quality-of-life measures for use in a wide variety of neurodegenerative, and related, conditions. This book is primarily concerned with the development, validation, and application of disease-specific measures. Such instruments are generally regarded as potentially more precise and sensitive to changes than more generic measures because they are intended to reflect the particular demands of specific conditions.

The first chapter documents established methods for the development and validation of instruments
and introduces readers unfamiliar with the area to the fundamental concepts of measurement in quality-of-life measurement. The following chapters document the current state of the art in measurement of Parkinson's disease, multiple sclerosis, motor neuron disease, progressive supranuclear palsy, multiple system atrophy, Huntington's disease, and dementia. The particular demands of measuring the health status of children are explored in the chapter on cerebral palsy. Although cerebral palsy is not a neurodegenerative disorder in itself, the impact of the condition on growth for children, and on aging for adults, often causes, over time, profound changes in functioning and health status. Consequently, the phenotype of cerebral palsy has been referred to as a “progressive neuromuscular” condition – hence its inclusion here. The impact of serious illness can have substantial effects on family members and friends, and these issues are explored in a chapter on quality of life and carers. The final chapters of the book explore methodologic issues in translation and scoring of instruments, as well as the place of more individualized measures that are specifically designed to reflect the concerns of individual patients. This book is intended to give a clear idea of the range of instruments available, as well as the issues involved in their development, validation, and application.